MedTrace Logo

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting

NCT03741829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-02-05

No results posted yet for this study

Summary

The purpose of this research study is to determine the amount of a protein named thymidine synthase that is being made by cancer and to develop laboratory models called PDX (patient derived xenografts) to learn more about SCLC (small cell lung cancer) and to begin testing new treatments.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • William Gmeiner, Ph.D, MBA · Wake Forest University Health Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2020-01-03
Completion
2020-01-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741829 on ClinicalTrials.gov